Cara Therapeutics Inc. (CARA) had a rough trading day for Tuesday December 03 as shares tumbled 34.56%, or a loss of $-8.945 per share, to close at $16.94. After opening the day at $20.69, shares of Cara Therapeutics Inc. traded as high as $20.70 and as low as $16.82. Volume was 5.64 million shares over 42,831 trades, against an average daily volume of n/a shares and a total float of 46.68 million.
As a result of the decline, Cara Therapeutics Inc. now has a market cap of $790.51 million. In the last year, shares of Cara Therapeutics Inc. have traded between a range of $27.55 and $12.19, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara’s most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara’s objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Cara Therapeutics Inc. is based out of Stamford, CT and has some 55 employees. Its CEO is Derek T. Chalmers.
Cara Therapeutics Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.